Veracyte offers its biopharma partners unique, multi-omic capabilities, expertise and tools designed to optimize biomarkers, companion diagnostics and therapeutic clinical trials through robust analysis of patient oncology samples. Our Immuno-oncology (IO) capabilities focus largely on the “immune contexture” of tumors (type, density, location and immune functions), which is strongly related to tumor progression and clinical outcome in patients. We utilize multiple technologies and proprietary artificial intelligence platforms and databases to help our biopharma partners advance precision medicine in the era of immuno-oncology and combination therapies.